Sum­it­o­mo Dainip­pon beefs up on­col­o­gy pipeline with $780M Tolero buy­out

Japan’s Sum­it­o­mo Dainip­pon Phar­ma has stepped up with a $200 mil­lion down pay­ment on its pur­chase of Salt Lake City-based Tolero Phar­ma­ceu­ti­cals. There’s an­oth­er $430 mil­lion set aside for de­vel­op­ment mile­stones plus up to $150 mil­lion in com­mer­cial pay­outs, bring­ing the to­tal deal to $780 mil­lion.

Tolero has been at work build­ing a case for its lead drug, the late-stage CDK9 in­hibitor alvo­cidib, as a com­bi­na­tion ther­a­py suit­ed to acute myeloid leukemia. By in­ter­fer­ing with a mech­a­nism in­volved in cell di­vi­sion and metas­ta­sis, Tolero be­lieves their drug has po­ten­tial to im­prove out­comes for a va­ri­ety of can­cers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER